INTRODUCTION

Cyclic nucleotide phosphodiesterases (PDEs), are the enzymes responsible for the hydrolysis of second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) and are classified into at least 11 major families regarding their substrate specificity, sequence similarity and sensitivity to inhibitor drugs\(^1,2\). Inhibitors of phosphodiesterase (PDEIs) have demonstrated various pharmacological properties including cardiotonic, vasodilator, smooth muscle relaxant, antidepressant, antithrombotic, bronchodilator, antiinflammatory, antioxidant\(^3-7\), increasing salivary flow rate and secretion of epidermal growth factor\(^8\) and enhancer of cognitive function such as learning and memory based on type of PDE inhibiting\(^9-12\). PDE-4 is a cAMP-specific enzyme, separated in four human isofoms (PDE-4 A, B, C and D)\(^13\) and represents a capable potential molecular target for the development of new antiasthmatic, antiinflammatory, autoimmune diseases and various gastrointestinal and neurological diseases\(^1,14-16\). Moreover than synthetic PDE-4 inhibitors, several natural ones derived from medicinal plants have been distinguished such as 3-O-methylquercetin from *Rhamnus nakaharai* and naringenin from citrus fruits\(^19\). Unfortunately, the development of PDE-4 inhibitors, such as rolipram and structurally-related compounds has been so far limited by several side effects, such as nausea, emesis, gastric acid secretion or central nervous system activation\(^1,17,18,20\). Thus, the design of novel, potent and selective second generation of PDE-4 inhibitors with reduced side effects represent a critical need in the pharmaceutical industry\(^15,18,21\). One way to increase both the potency and the selectivity of PDE-4 inhibitors and thus improving the therapeutical index, is to develop new compounds featuring original chemical structures, different than those of the known PDE-4 inhibitors\(^22\), if the side effects are not mechanism-based.

The present study extends our work on addition reaction of organolithium (\(n\)-butyllithium) with a ketone (cyclopentanone). Present study describes the preparation of 1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclopentanol (6) as potential phosphodiesterase-4 inhibitor from two methods (A, B).

KEY WORDS: Phosphodiesterase, Cyclic adenosine monophosphate, Mammalian organs.

EXPERIMENTAL

All chemicals and reagents were obtained from Merck Chemical Company (Darmstadt, Germany). Melting points were determined using Kofler hot stage apparatus and are uncorrected. The IR spectra were taken using a Shimadzu 470 spectrophotometer (potassium bromide disks). The mass spectra were run on a GC-Mass model: 5973 network mass selective detector, Gc 6890 Agilent. \(^1\)H NMR spectra were recorded using a Varian 400 spectrometer and chemical shifts are expressed as \(\delta\) (ppm) with tetramethyl silane (TMS) as internal standard. The purity of the synthesized compounds was confirmed by thin layer chromatography (TLC) using various solvents of different polarities. Merck silica gel 60 F\(_{254}\) plates.
were applied for analytical TLC. Column chromatography was performed on Merck silica gel (70-230 mesh) for purification of compounds.

**Preparation of 2-methoxymethyl acetate** (2): A mixture of 2-methoxy phenol (1) (1.24 g, 10 mmol) and acetic anhydride (20 mL) was added two drops of conc. H$_2$SO$_4$ with vigorous stirring. The reaction mixture was heated at 100 °C for 7 h and then allowed to cool to 25 °C and stirring continued for 3 h (monitored by TLC). The organic layer was separated and the aqueous layer was extracted with ether (3 × 15 mL). The combined ether extracts were washed with water (15 mL) followed by brine (15 mL) and concentrated under reduced pressure to give crude product, which was further purified by vacuum distillation to afford acetate 2 (1.60 g). Yield: 96%; colourless liquid; $^1$H NMR (400 MHz, CDCl$_3$): δ 2.3 (s, 3H), 3.8 (s, 3H), 6.91-7.25 (m, 4H); MS (m/z, % rel intensity): (M$^+$ 166), 124, 109, 95, 91, 81, 77, 64; IR (KBr, v$_{max}$ cm$^{-1}$): 3070, 3010, 2944, 2841, 1770.

**Preparation of 5-bromo-2-methoxymethyl acetate** (3): A solution of 2-methoxy acetate (2) (1.29 g, 7.81mmol) and NBS (1.41 g, 8.6 mmol) in dry CH$_2$Cl$_2$ (18 mL) was heated at 60 °C under argon atmosphere for 10 h. The resulting reaction mixture was cooled to room temperature. The organic layer was separated and the aqueous layer was extracted with EtOAc (2 × 15 mL). The combined organic extracts were washed with a saturated solution of sodium sulfite (20 mL) and K$_2$CO$_3$ (6.4 g) and extracted with EtOAc (2 × 15 mL). The combined organic extracts were washed with water (15 mL) followed by brine (15 mL) and concentrated under reduced pressure to give crude product which was purified by column chromatography on silica gel using petroleum ether/EtOAc (9:1) to give crude product, which was further purified by column chromatography on silica gel using petroleum ether/EtOAc (9:1) as eluent to afford bromo ether/ EtOAc (9:1) as eluent to afford bromo ether 3 (1.2 g). Yield: 88%; yellowish liquid; $^1$H NMR (400 MHz, CDCl$_3$): 1.2-2.0 (m, 8H), 3.8 (s, 3H), 4.73 (m, 1H), 6.71 (d, $J = 8$ Hz, 1H), 6.97 (s, 1H), 6.98-7.15 (m, 1H); MS (m/z, % rel intensity): (M$^+$ 272, 17), 270 (17), 202 (100), 187 (44), 173 (4), 159 (8), 142 (4), 123 (5), 108 (5), 94 (7), 79 (10), 63 (7); IR (KBr, v$_{max}$ cm$^{-1}$): 2959, 2871, 2388, 1586, 1505.

**Preparation of 1-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclopentanol** (6)

**Method A:** A mixture of magnesium splinters (0.05 g, 2.08 mmol) and 4-bromo-2-(cyclopentyl)phenol 5 (0.5 g, 1.85 mmol) in dry THF (10 mL) was stirred under argon atmosphere. The mixture was stirred gently and heated until the reaction started. The reaction had been maintained until all magnesium was disappeared. The mixture was cooled to room temperature and cyclopentanone (0.17 g, 2.06 mmol) in 10 mL of dry THF was added dropwise and the resulting solution was refluxed for 2 h. The reaction was stopped by adding 20 mL of saturated NH$_4$Cl and extracted three times with 10 mL portions of ether. The organic layer was separated, washed with NaOH solution (10 %, 10 mL) followed by water (10 mL). The organic layer was dried over sodium sulfate and the solvent was evaporated. The resulting product was purified by column chromatography on silica gel using petroleum ether/EtOAc (9:1) to give 1-(3-(cyclopentyl)oxy)-4-methoxyphenyl)cyclopentanol (6) as yellowish liquid. Yield: 11%; $^1$H NMR (400 MHz, CDCl$_3$): 1.2-2.1 (m, 16H), 1.95 (s, 1H), 3.81 (s, 3H), 4.78 (m, 1H), 6.79 (d, $J = 8$ Hz, 1H), 6.97 (d, $J = 8$ Hz, 1H), 7.05 (s, 1H); MS (m/z, % rel intensity): (M$^+$ 276, 6), 258 (33), 208 (6), 190 (100), 175 (22), 159 (22), 143 (4), 129 (11), 115 (9), 91 (9), 77 (6), 67 (9); IR (KBr, v$_{max}$ cm$^{-1}$): 3427, 2958, 2870.

**Method B:** A solution of 4-bromo-2-(cyclopentyl)-1-methoxybenzene 5 (0.5 g, 1.85 mmol) in dry THF (10 mL) was cooled to -78 °C and n-butyl lithium (1.5 M, 1.2 mL) was added slowly by syringe (0.5 h) at the same temperature. Then a solution of cyclopentanone (0.14 g, 1.7 mmol) in dry THF (3 mL) was added dropwise and the mixture was stirred at -78 °C for additional 0.5 h. The mixture was reached to room temperature and stirred for 2 h. The reaction was quenched by adding saturated NH$_4$Cl solution (10 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3 × 15 mL). The combined organic extracts were washed with water (15 mL) followed by brine (15 mL) and concentrated under reduced pressure to give crude product which was further purified by column chromatography on silica gel using petroleum ether/EtOAc (9:1) as eluent to give 1-(3-(cyclopentyl)-oxy)-4-methoxyphenyl)cyclopentanol (6). Yield: 16%; yellowish liquid; $^1$H NMR (400 MHz, CDCl$_3$): δ 1.2-2.1 (m, 16H), 1.95 (s, 1H), 3.81 (s, 3H), 4.78 (m, 1H), 6.79 (d, $J = 8$ Hz, 1H), 6.97 (d, $J = 8$ Hz, 1H), 7.05 (s, 1H); MS (m/z, % rel intensity): (M$^+$ 276, 6), 258 (33), 208 (6), 190 (100), 175 (22), 159 (22), 143 (4), 129 (11), 115 (9), 91 (9), 77 (6), 67 (9); IR (KBr, v$_{max}$ cm$^{-1}$): 3427, 2958, 2870.
RESULTS AND DISCUSSION

Reaction sequence employed for the synthesis of 1-[3-(cyclopentyl-oxy)-4-methoxyphenyl]cyclopentanol (6) is shown in Scheme-I. Starting material 2-methoxy phenol (1) was converted into 2-methoxyphenyl acetate (2). Compound 2 on reaction with NBS in dry CH₂CN yielded 5-bromo-2-methoxyphenyl acetate (3) in good yield. 5-bromo-2-methoxyphenol (4) was obtained by refluxing 3 with 10 % NaHCO₃ in methanol under argon atmosphere. Similarly, 4-bromo-2-(cyclopentyl)-1-methoxybenzene (5) was synthesized by heating compound 4 with cyclopentyl bromide in DMF at 50 °C. The synthesis of 6 from method A: compound 5 was reacted with magnesium splinters in dry THF. After heating the solution, cyclopentanone was added dropwise under argon atmosphere to give compound 6. The synthesis of 6 from method B: the reaction of compound 5 with n-butyl lithium in dry THF at -78 °C gave aryllithium. Then a solution of cyclopentanone in dry THF was added dropwise (Scheme-I). Both of the method (A and B) gave 1-[3-(cyclopentyl-oxy)-4-methoxyphenyl]cyclopentanol (6) in low yield.

Scheme-I: Synthesis of 1-(3-(cyclopentyl-oxy)-4-methoxyphenyl)cyclopentanol from 2-methoxy phenol. Conditions: (a) Ac₂O, conc. H₂SO₄, 100 °C, 7 h, 96 %; (b) NBS, CH₂CN, 60 °C, 10 h, 95 %; (c) aq. 10 % NaHCO₃, MeOH, reflux, 3 h, 93 %; (d) cyclopentyl bromide, K₂CO₃, DMF, 50 °C, 12 h, 88 %; (e) Method A: Mg, cyclopentanone, THF (dry), reflux, 2 h, 11 %; Method B: BuLi, cyclopentanone, THF (dry), -78 °C, 0.5 h, 16 %

Conclusion

1-[3-(Cyclopentyl-oxy)-4-methoxy-phenyl]cyclopentanol (6) has been synthesized as potential phosphodiesterase-4 inhibitor.

REFERENCES


ACKNOWLEDGEMENTS

This work was supported by grants from Tehran University of Medical Sciences and Iran National Science Foundation (INSF).